Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: interim guidance, 8 January 2021

Background

This interim guidance has been developed based on the advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) at its 5 January 2021 extraordinary meeting.

Methods

SAGE applies the principles of evidence-based medicine and has set in place a thorough methodological process for issuing or updating recommendations. Specifically for COVID-19 vaccines, a detailed description of the methodological processes can be found in the SAGE evidence framework for COVID-19 vaccines. This framework is intended to offer guidance for considering data emerging from clinical trials in support of issuing vaccine-specific evidence-based recommendations.